ERBB2 and neoplasm: The great advantage is that it stimulates CD8+ cytotoxic and memory T cells, which bind human leukocyte antigen (HLA) molecules on APCs to recognize, neutralize, and destroy HER2-expressing primary tumor cells and metastatic tumors [52,53].